<?xml version="1.0" ?>
<document id="525511c3e146527c02bc25aed2833f0ef103d62a">
  <chunk id="525511c3e146527c02bc25aed2833f0ef103d62a.c0" text="IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes">
    <entity charOffset="77-81" id="525511c3e146527c02bc25aed2833f0ef103d62a.c0.e0" ontology_id="DOID_3083" text="COPD" type="disease"/>
  </chunk>
  <chunk id="525511c3e146527c02bc25aed2833f0ef103d62a.c1" text="Background: Interferon lambdas (IFNLs) have important anti-viral/bacterial and immunomodulatory functions in the respiratory tract. How do IFNLs impact COPD and its exacerbations? Methods: Five hundred twenty eight patients were recruited in a prospective observational multicentre cohort (PROMISE) study. The genetic polymorphisms (rs8099917 and rs12979860) within the IFNL3/4 gene region and circulating levels of IFNL3 in COPD patients were determined and associated with disease activity and outcome during a median follow-up of 24 months.">
    <entity charOffset="12-22" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e0" ontology_id="CHEBI_52999" text="Interferon" type="chemical"/>
    <entity charOffset="152-156" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e1" ontology_id="DOID_3083" text="COPD" type="disease"/>
    <entity charOffset="282-288" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e2" ontology_id="CHEBI_34935" text="cohort" type="chemical"/>
    <entity charOffset="425-429" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e3" ontology_id="DOID_3083" text="COPD" type="disease"/>
    <entity charOffset="475-482" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e4" ontology_id="DOID_4" text="disease" type="disease"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e0" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e1" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p0" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e0" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e3" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p1" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e0" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e4" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p2" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e1" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e2" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p3" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e2" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e3" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p4" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e2" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c1.e4" id="525511c3e146527c02bc25aed2833f0ef103d62a.c1.p5" relation="true"/>
  </chunk>
  <chunk id="525511c3e146527c02bc25aed2833f0ef103d62a.c2" text="Results: The GG genotype significantly influenced severe exacerbation rate (42 vs. 23%; p = 0.032) and time to severe exacerbation (HR = 2.260; p = 0.012). Compared to the TT or TG genotypes, the GG genotype was associated with severe dyspnoea (modified medical research council score ≥ median 3; 22 vs 42%, p = 0.030). The CC genotype of the rs12979860 SNP was associated with a poorer prognosis (body mass index, airflow obstruction, dyspnea and exercise capacity index ≥ median 4; 46 vs. 36% TC vs. 20.5% TT; p = 0.031). Patients with stable COPD and at exacerbation had significantly lower circulating IFNL3 compared to healthy controls (p &lt; 0.001 and p &lt; 0. 001, respectively). Circulating IFNL3 correlated to post-bronchodilator FEV 1 %predicted and the tissue maturation biomarker Pro-collagen 3. Conclusion: IFNL3/4 polymorphisms and circulating IFNL3 may be associated with disease activity and outcomes in COPD. Trial registration: Clinical Trial registration http://www.isrctn.com/ identifier ISRCTN99586989 on 16 April 2008.">
    <entity charOffset="545-549" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e0" ontology_id="DOID_3083" text="COPD" type="disease"/>
    <entity charOffset="778-787" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e1" ontology_id="CHEBI_59163" text="biomarker" type="chemical"/>
    <entity charOffset="883-890" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e2" ontology_id="DOID_4" text="disease" type="disease"/>
    <entity charOffset="916-920" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e3" ontology_id="DOID_3083" text="COPD" type="disease"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e0" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e1" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.p0" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e1" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e2" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.p1" relation="true"/>
    <pair e1="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e1" e2="525511c3e146527c02bc25aed2833f0ef103d62a.c2.e3" id="525511c3e146527c02bc25aed2833f0ef103d62a.c2.p2" relation="true"/>
  </chunk>
</document>
